EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler reiterates a Buy rating on Adaptimmune Therapeutics (NASDAQ:ADAP) and maintains a $10 price target.
May 26, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Tony Butler reiterates a Buy rating on Adaptimmune Therapeutics and maintains a $10 price target.
The reiterated Buy rating and maintained $10 price target by EF Hutton analyst Tony Butler indicates a positive outlook for Adaptimmune Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100